secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001493152-23-009109
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows
--------------------------------------------------------------------------------

- Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.
- Full year net revenue $31.8M, down 4% due to ThyGeNEXT reimbursement decline ($3.6M impact).
- Full year loss from continuing ops improved to $(5.9)M from $(7.0)M; adjusted EBITDA $(1.2)M vs $(2.0)M.
- Cash balance $4.8M at Dec 31, 2022, up from $2.9M at Dec 31, 2021.
- Management cites expense reductions and volume growth partially offsetting price headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer